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Project Abstract 
Introduction: Cystic pancreatic tumours constitute the second-most prevalent group of 
tumours after ductal adenocarcinoma of the pancreas. They are broadly categorized 
histopathologically as mucinous and non-mucinous. Mucinous cystic tumours, which comprise 
intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN), display 
a greater predisposition for conversion to malignancy as compared to their non-mucinous 
counterpart serous cystadenoma (SCN). Typically, cystic tumours are diagnosed when they 
became symptomatic, owing to growth in size or malignant transformation whereby invasion of 
gastric wall and splenic vein leads to bleeding gastric varices.  
Problem: With the advent of modern imaging, cystic tumours are being detected incidentally 
with increasing frequency at a stage when they are very small, asymptomatic and unlikely to 
have malignant transformation. Indiscriminate pre-emptive resection of cystic tumours with 
malignant potential is not feasible owing to the great morbidity associated with resection 
procedures. Hence patients with cystic tumours of malignant potential need to be carefully 
chosen for resection. There exists no single diagnostic tool that can accurately discriminate 
between mucinous and non-mucinous cystic pancreatic neoplasms except for histopathology 
which is only possible after resection of tumour. Consensus guidelines exist for non-invasive 
identification of tumour histological category using radiological features as surrogates. The 
process of diagnosis remains dependant on expert opinion. The goal of this study is to harness 
demographic and radiological features with potential capacity to discriminate among cystic 
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pancreatic neoplasms, as reported in consensus guidelines and literature, to form a simplified 
predictive tool. 
Methods: Excluding children and adolescents, all cases of cystic masses, with a 
histopathological diagnosis confirmed as SCN, IPMN or MCN, between 1995 to date were 
searched in a prospectively maintained database. Data on symptoms at presentation (if any) 
and computed tomography features (CT), magnetic resonance imaging features (MRI), 
endoscopic ultrasound features (EUS) were stored. A statistical tree based algorithm was run on 
the data to develop a decision tree that will predict for the three types of cystic neoplasms. The 
performance of the decision tree was assessed using a receiver operating curve surface (ROCS) 
and volume under the surface (VUS). 
Results: The VUS for the decision tree was 77.5% which means that the decision tree correctly 
classified SCNs, IPMNs and MCNs in 77.5 % of all cases. The empirical 95% confidence interval 
for the VUS was 54.5% - 78.5%. of 36.2% of SCNs that were misclassified as IPMNs or MCNs and 
15.9% of non-SCN cases that were misclassified as SCNs. 
Conclusion: The decision tree offers a fairly accurate, yet simplified, means of predicting for the 
histology of cystic pancreatic lesions and is therefore capable of supporting decisions in clinical 
management of these patients. The accuracy of the decision tree may be raised higher by 
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1. Introduction 
1.1 General Information 
The WHO classifies pancreatic tumours histopathologically according to cell of origin followed 
by malignant potential. The most frequent pancreatic tumours are those that arise from the 
epithelial cells of the pancreas of which the most common is ductal adenocarcinoma, a solid 
malignant tumour that is traditionally known to be responsible for 85% of all pancreatic 
tumours. (1) The remainder of the epithelial tumours are cystic neoplasms of varying malignant 
potential. True incidence of these cystic neoplasms is hard to estimate considering the rarity of 
the disease as well as the fact that not all cystic tumours may become symptomatic such that 
necessitates presentation to a healthcare facility. Early surgical series that first attempted to 
characterise these tumours are characterised by a small cohort of patients (2) and Kimera et al., 
in an autopsy series of 300 cases, identified the presence of cystic neoplasms in 73 cases 
(24.3%) where the tumour was not the probable cause of death. (3) 
The most notable tumours in the cystic category in terms of incidence are intraductal papillary 
mucinous neoplasms (IPMN), serous cystadenoma (SCN) and mucinous cystic neoplasms (MCN) 
in that order.  
Serous cystic adenomas are benign tumours that appear histopathologically as “glycogen-rich, 
ductular-type epithelial cells that produce a watery fluid similar to serum”. (1)These cells are 
found lining fibrous septae that are rich in capillary vessels. Often the fibrous septae will 
converge to a dense fibrous core which is seen grossly as a stellate scar. (4) Normally, such 
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septations give the tumour the appearance of possessing many small cysts whereupon the 
tumour is labelled as microcystic. However, there is another manifestation of SCNs which 
contains larger (1 – 2 cm in diameter) and fewer cysts that may protrude into the pancreatic 
parenchyma, labelled as the oligocystic variant also known as the macrocystic variant.  Seventy 
percent of cases are in females when both variants are taken into account (1) and this 
propensity is largely driven by the affinity of the more common microcystic variant to that 
gender; the oligocystic variant is seen equally in both genders. (5) SCNs frequently occur in the 
body or tail of the pancreas (1) although, once again, this is largely because the more common 
microcystic variant is invariable found in these regions. The macrocystic variant is more 
commonly observed in the head of the pancreas where it may exert mass effect on the biliary 
tree resulting in obstructive jaundice. (6)  
Mucinous tumours, as the name asserts, are characterised by excessive production of mucus 
which distinguishes them from SCNs. Intraductal papillary mucinous neoplasms (IPMN) are 
defined by Klöppel et al. as category of “tumours that are grossly visible, mucin-producing, 
cystic tumours growing within the pancreatic ducts and forming papillary projections”. They 
occur within the pancreatic ducts and are therefore classified according to whether they occur 
in the main pancreatic duct or branch pancreatic ducts. Columnar mucin-containing cells line 
the ducts and form pseudopapillary structures. (1) The excessive production of mucus 
combined with the mass effect of the pseudopapillary structures usually leads to dilation of the 
duct distal to the location of the IPMN.  Therefore they are not truly cystic but appear cystic 
due to the pseudopapillary structures protruding into the dilated pancreatic duct, interspersed 
by mucus. When the IPMN occurs in the main duct, the portion of the duct distal to the tumour 
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is seen to be markedly dilated, often greater than 1 cm, on gross appearance. However, when 
the IPMN occurs in the branch duct this gross dilation does not occur and the tumour instead 
takes the form of a singular cysts or a cluster of cysts, often referred to as a “cluster of grapes” 
appearance. (7) IPMNs are seen slightly more in more in males with a female to male ratio of 
1:1.5 and are 80% of instances are observed in the head of the pancreas. These tumours 
gradually undergo increasing dysplastic changes to eventually become invasive carcinoma of 
the pancreas. (8) 
Similarly, mucinous cystic neoplasms (MCN) are also composed of columnar epithelium that 
produces mucin, progresses along degrees of dysplastic changes to eventually become invasive 
carcinoma (5) and additionally is supported by an ovarian-like stroma. (1) MCNs are typically 
multilocular and fairly large at the time of diagnosis (60 – 100 mm). Furthermore, the wall of 
the cysts has mural nodules and papillary projections towards the lumen except in case of the 
more infrequent unilocular variants which have smooth walls. (8) In contrast to IPMNs, 
however, they do not communicate with the pancreatic ductal system with a proclivity towards 
the body and tail regions of the pancreas. Additionally, MCNs are found almost exclusively in 
women over a broad age range excepting childhood and adolescence. (5)  
Radiological imaging reflects the differences in gross appearance between the kinds of 
pancreatic cysts. CT shows serous cystadenomas as a collection of six or more small cysts, again 
up to 2 cm in size, with a “spongy” appearance displaying soft-tissue or mixed attenuation with 
enhancement of septae. SCNs may or may not display the classical central stellate scar. The 
tumours are often well marginated and the boundaries may be smooth or lobulated. The 
oligocystic variant may be difficult to differentiate from a mucinous cystadenoma as it may 
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appear as a large unilocular cysts or may contain fewer large cysts > 2cm. MCNs appear as 
multilocular, macrocystic lesions (> 2cm) lesions with smooth boundaries that may have 
peripheral calcification and that may contain septations. Their large size may cause partial 
obstruction of the pancreatic ductal system and so dilated ducts may be seen. (9,10) Main duct 
IPMNs can mimic an MCN if it involves only a segment of the main pancreatic duct or may 
manifest as diffuse dilation when the entire main pancreatic duct is involved. In either case, 
papillary nodules may be seen protruding from the walls and the walls appear thickened and 
enhance on contrast. Branch-duct IPMNs appear as a lobulated collection of cysts of any 
number around a local branch duct dilation and normal main pancreatic duct calibre. (11) 
Endoscopic ultrasound (EUS) findings are interpreted in conjunction with CT images on the 
basis of morphology and cyst fluid analysis. (12) The main features of interest are the size of 
cysts, the shape of the margins of cysts and the walls of the cysts. Serous cystadenomas 
continue the trend of appearing as lobulated, multiloculated lesions with an occasional central 
scar. They may display echogenic foci or may appear as a hypoechoic cystic/solid mass. (13) The 
exception is that of the macrocystic variant which appears remarkably similar to MCN on CT 
and MRI in that both are unilocular. However, on EUS, MCNs display thick walls and peripheral 
calcifications and loculations whereas the unilocular SCNs display microcystic components of 
less than 2 mm in size. (14,15) Pancreatic ductal dilation idiosyncratic to IPMNs is also seen in 
EUS along with thickened hyperechoic walls of the dilated ducts accompanied with hypoechoic 
mass within with solid and cystic components of variable size. (13) 
EUS affords the opportunity to aspirate fluid within the cysts which also reveals differences 
when analysed for brush cytology, pancreatic enzymes and tumour markers. (7) Aspirates from 
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serous cystadenomas are typically acellular whereas mucinous cysts have a good cellular yield. 
When yield is obtained, cells can be assessed on brush cytology according to cellular 
descriptions mentioned previously.  Carcinoembryonic antigen (CEA) levels are generally higher 
in mucinous lesions than serous lesions. Brugge et al. report a mean and median of 5607 ng/mL 
and 500 ng/mL for mucinous lesions as opposed to 284 ng/mL and 21 ng/mL for serous lesions 
respectively. This difference in CEA concentration is corroborated by a multicentre review by 
Van der Waaij et al. who observed that a CEA > 800 ng/mL is strongly suggestive of mucinous 
cystadenoma and a CEA < 5 ng/mL is strongly suggestive of serous cystadenoma as is a Cancer 
Antigen 19-9 < 37 ng/mL. Similarly, both studies found that cyst fluid from mucinous lesions 
have higher amylase and lipase levels than serous lesions. (16,17) 
MRI shows serous cystadenomas to be a cluster of small cysts (“honeycomb pattern”) each of 
which range between 0.1 – 2 cm in size. The exception is the oligocystic variant whose cysts are 
fewer in number and appear larger. These cysts do not communicate with the pancreatic ductal 
system, their walls enhance in the delayed phase of contrast enhanced T1-weighted images and 
their lumens display simple fluid signal intensity on T2-weighted images which is in keeping 
with the presence of serous fluid. As the lesion grows as a whole, fibrous tissue retraction 
distorts the architecture of central cysts which may collapse to form a central scar. This scar 
may become calcified leading to a signal void on MRI. (18) The varying amounts fibrous tissue 
seen across cysts means that ADC values on diffusion-weighted images will vary, making the 
latter a poor choice for diagnosis. (19) 
MCNs usually appear, on MRI, as round or lobular uniloculated lesions with low signal intensity 
on T1-weighted imaging and high signal intensity with T2-weighted imaging. Cysts are often 
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seen to be larger than 2 cm and a few septae may be seen when the lesion is multiloculated 
(20%). The walls show enhancement on delayed gadolinium enhanced, fat-supressed T1-
weighted images, reflecting fibrotic changes, as well as high ADC values and 16% of cases may 
exhibit peripheral calcifications. IPMNs have a varied appearance on MRI depending on the 
type that is found. In all cases, a clear communication with the pancreatic ductal system is 
clearly visualised in the background of pancreatic parenchyma that has generally low signal 
intensity reflective of atrophic changes. If the main pancreatic duct is involved then, as in CT, 
the dilation may be diffuse or segmental according to extent of involvement. If branch duct is 
involved, then only local ductal dilation is observed on T2-weighted images. ADC values are 
elevated on diffusion-weighted imaging along the length of the duct involved due to the 
presence of mucous. The tumour itself is usually no visualised; its presence is inferred from the 
multifocality of the lesions observed. (18–20) 
1.2 Rationale & Background Information 
Ganjoux et al., in their retrospective review of a prospectively maintained registry of 1424 
patients diagnosed with pancreatic cysts, show that cystic pancreatic neoplasms are being 
detected with greater frequency with the advent of non-invasive imaging techniques. 
Furthermore, they are being detected at a stage where they are small in size and when they 
generally lack features indicative of malignancy. (21) Incidentally-detected cystic pancreatic 
neoplasms now pose a significant diagnostic and management challenge owing to the lack of 
information of their natural history and diagnosis at very early stage. (22) While the WHO 
classification helps surgeons understand the malignant potential of each tumour, there is no 
information as to why and at what point in time these tumours transform to malignancy. It 
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appears that SCNs, MCNs and IPMNs progress at different rates, along an adenoma carcinoma 
sequence and the malignant end of the spectrum manifests as cystadenocarcinoma for the 
former two and invasive carcinoma for the latter. The prognosis of these malignant forms 
depends on the degree of spread. (1) 
A variety of surgical procedures may be employed for resection of cystic neoplasms depending 
on location of the tumour and secondarily on the size of the tumour.  These include Whipple 
procedure, total pancreatectomy, segmental resection, enucleation and distal pancreatectomy 
that may or may not be spleen preserving. (21,23) Generally these procedures carry great 
morbidity in the post-operative period (43%) exhibiting complications such as cardiopulmonary 
event, fistula, delayed gastric emptying and sepsis.(24) 
The lack of aggressiveness typically seen in cystic neoplasms of the pancreas coupled with their 
high rate of serious morbidities seen in surgical procedures for their resection make 
indiscriminate resection of all cystic neoplasms unjustified. Conversely, the potentially lethal 
nature of a cystic neoplasm that has undergone malignant transformation demands that due 
attention be paid to all incidentally discovered cystic pancreatic lesions. This need for attention 
is further highlighted by the fact that cystic pancreatic neoplasms, while constituting a minority 
of pancreatic tumours, are virtually curable by resection. Therefore, there is a need for an 
efficient process of selection of surgical candidates in whom the risks of malignant 
transformation of the cystic lesion are balanced by the hazards of the surgical procedure 
employed to resect that lesion. 
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Histopathological analysis of resected cystic pancreatic neoplasms has afforded tremendous 
insight into the characteristics of these tumours and is the most reliable means of distinguishing 
them. (25) Unfortunately the cost of obtaining a specimen for histopathology is the 
employment of the very surgical procedures that inflict morbidity on patients. Much work has 
been done over the past decade to replicate the accuracy of histopathology via non-invasive or 
minimally invasive means. Computed tomography (CT), magnetic resonance imaging (MRI), 
endoscopic ultrasound (EUS) and tumour marker analysis of cyst fluid aspirate have been most 
successful in this regard. 
The sensitivity and specificity of these imaging modalities has been judged for each imaging 
feature that is thought to reflect a certain histopathological type of cystic neoplasm. The most 
widely explored imaging features in the literature are septations, mural nodules, main 
pancreatic duct dilation and communication of cystic lesion with pancreatic duct. Table 1 
highlights some literature that explores the utility of these features in predicting for the 
presence of malignancy in a detected cystic pancreatic lesion. 
Table 1: Utility of Cyst Features in Predicting Histology of Pancreatic Cysts (26: Sahani et al., 27 Manfredi et al.) 
Imaging Feature Statistic and Reporting Author 
Cyst Septations 73.9 % Sensitivity (26) (only done for IPMNs) 
Present in 35.7 % MCNs vs. 64.3 % of SCNs (27) 
Mural Nodule(s) 93 % Sensitivity, 80 % Specificity (26) (only done for IPMNs) 
Present in 94.1 % MCNs vs. 5.1 % of SCNs (27) 
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Cyst Wall Thickness  2- 4 mm in MCNs vs. 2 – 3 mm in SCNs (27) 
Largest Cyst Diameter 40 – 73 mm in MCNs vs. 20 – 44 mm in SCNs (27) 
While some of these numbers are impressive, there is a further complication: no single imaging 
modality has actually been found to be reliable in detecting the presence of these features. 
Table 2 summarises the interobserver agreement (ICC) in assessing the presence of certain 
features on various imaging modalities. 
Table 2: Interobserver agreement in Ascertaining Presence of Cyst Features on Imaging Modalities (14: Kadiyala et 
al., 26: Sahani et al., 28: Jong et al., 29: Do et al.) 
 
Imaging Feature Interobserver 
Agreement  
Modality Author 
Cyst Septations 0.36  MRI (28) 
0.24 EUS (26) 
Mural Nodule(s) 0.28 CT (29) 
0.23 MRI (28) 
0.42 EUS (14) 
Main Pancreatic 
Duct Dilation 
0.75    CT (28,29) 
Communication of 
Cystic lesion with 
Pancreatic Duct 
0.53 MRI (28) 
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Jong et al. found that the overall agreement for discriminating between mucinous and non-
mucinous cysts was 0.36. (29) 
The varying sensitivities, specificities, inter-observer agreements of each of these methods as 
well as the varying definitions used in these studies motivated the formulation of consensus 
guidelines on the clinical usage of diagnostic modalities to guide a multidisciplinary approach to 
diagnosis. The first international consensus on diagnosis and management of cystic pancreatic 
neoplasms was published in 2006 when a multidisciplinary panel of experts convened in Sendai, 
Japan. (30) This consensus guideline was revised in 2012, owing to the availability of additional 
literature, by another panel of experts who convened in Fukuoka, Japan. (33) Additionally, 
European consensus guidelines were also published in 2013. (31) 
The Fukuoka consensus recommends that all patients with suspected cystic neoplasms of 
greater than 1 cm diameter undergo pancreatic-protocol CT or gadolinium-enhanced MRI with 
magnetic resonance cholangiopancreatography (MRCP). Asymptomatic cysts that are < 1 cm 
size have rarely been seen to harbour malignant elements and therefore no further workup is 
needed. 
Management is currently guided by the findings of  
● cyst size > 3 cm 
● “Worrisome features” (thickened cyst walls, main pancreatic duct (MPD), calibre of 5 – 9 
mm, an abrupt change in MPD calibre with distal pancreatic atrophy, non-enhanced 
mural nodules, lymphadenopathy)  
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● “High risk stigmata” (obstructive jaundice with cystic lesion of pancreatic head, 
enhanced solid component, MPD size > 10 mm). 
If none of these is found, the patient is followed by serial imaging. In this case, additional 
information regarding the risk of malignancy is afforded by determining the type of cystic mass. 
Clues towards determining type of cystic mass are elicited by examining morphology, 
multiplicity, location, and communication with MPD on imaging, as well as CEA and cytology of 
fine needle aspirates. CEA helps distinguish mucinous from non-mucinous cysts but does not 
discriminate malignant from benign lesions. Dysplastic cells seen on cytology give clues towards 
malignancy but this is only recommended in centres with expertise. 
Having identified these features in the consensus, the surgical community now has a guided 
pathway (32) to organize multidisciplinary efforts in diagnosis. The guided pathway allows 
utilization of radiological and biochemical features with aforementioned sensitivities and 
specificities in a manner that maximally allows differentiation between malignant and non-
malignant cysts. Goh et al. found the positive and negative predictive value of a patient being 
classified as high risk for malignancy as per the revised 2012 Fukuoka guidelines to be 88% and 
92.5% respectively. (33) 
While differentiating between malignant and non-malignant cysts is a key question in clinical 
management, the consensus guidelines still miss out on the primary instinct that clinicians 
adopt in the management of any disease which is to assess the natural history of the disease. 
The consensus guidelines do not primarily address the matter of predicting for the histological 
subtype of the pancreatic cyst while this knowledge is still expected to be employed in clinical 
judgement. It is difficult to assess for malignancy without trying to gain an idea of the 
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histological type of the lesion since features that otherwise predict for malignancy are 
sometimes also found in SCNs which are less predisposed to malignant transformation. 
Furthermore, there is a net loss of sensitivity over the steps of the pathway as features are 
tested sequentially rather than simultaneously. Demographic characteristics that do show a 
differential distribution over tumour categories, such as age and gender, are not directly 
included in the diagnostic pathway yet are expected to be employed in clinical judgement while 
diagnosing the cyst. All-in-all, significant expertise in clinical judgement is required to overcome 
the subjective elements of the diagnostic process namely the poor inter-observer agreement in 
detecting these features as well as the need to judge the underlying histology of the cyst.  Such 
expert clinical judgement is time-consuming to develop and potentially restricted to high 
volume centres. Kleeff et al. found that 10% of patients were misclassified preoperatively and 
could potentially have avoided surgery. (23) 
1.3 Study Goals and Objectives 
The goal of this study is to provide a tool that will simplify the non-invasive detection of the 
histology of pancreatic cystic lesions for general and pancreatic surgeons, a process that 
otherwise requires expert clinical judgement, by harnessing elements of clinical judgement in a 
statistically guided framework. 
The objective of the study is to apply a statistical classification method to case-specific 
demographic and radiological information. The statistical method must be such that it provides 
an explicable rule by which surgeons may be able to discriminate between Serous Cystic 
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Neoplasms, Mucinous cystic neoplasms and Intraductal Papillary Mucinous Neoplasms with test 
characteristics that make it equivalent to, if not better than, experienced surgical opinion. 
2. Methodology 
2.1 Patient Selection 
In this cross-sectional study, inpatients and outpatients with a confirmed histopathological 
diagnosis of either SCN, MCN or IPMN since year 1990 to date of age greater than 18 years 
were queried from a prospectively maintained database at the Johns Hopkins Medical 
Institutions dedicated to cystic pancreatic pathologies. Patients of age 18 and below were 
excluded since the distribution of cystic pathologies seen in that age group is not of primary 
interest in this study. The following data were either extracted from this database or from the 
Johns Hopkins electronic medical record regarding the patients that resulted from the query 




4) Symptoms and signs, if any, at presentation 
a) Pruritus 
b) Jaundice defined as yellow discolouration of eyes and/or skin either reported by the 
patient or noted by the examining clinician  
c) Weight Loss as defined as a loss of 10 lbs or subjective feeling of loosening of 
clothing 
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d) Abdominal Pain 
e) Past History of any malignancy 
f) Past History of diabetes mellitus 
5) Family History of pancreatic malignancy, cystic or otherwise 
6) The following CT, MRI and endoscopic ultrasound image findings as reported by the 
clinical radiologist seeing the patient regarding the largest cystic lesion present in the 
patient at the time of presentation 
a) Cyst Largest Diameter 
b) Location of cyst 
c) Presence of a thick cyst wall, where thick is defined as greater than 2 mm 
d) Presence of calcification(s) in the cyst  
e) Presence of septations(s) in the cyst 
f) Presence of mural nodule(s) in the cyst 
g) Presence of main pancreatic duct dilation in the pancreas 
h) Presence of common bile duct dilation 
This yielded 900 cases with 1804 total images. 
Following this inclusion, patients placed on radiological surveillance upon diagnosis were 
excluded from the results since they did not have a definite histological confirmation of 
diagnosis. Furthermore, repeat images of the cystic lesion of patients who were placed on 
surveillance prior to obtaining a definite histological confirmation of the diagnosis were 
discarded. This is because the classification tree method is currently not implemented for 
 15 
longitudinal or panel data (see Model Development for details). Patient with multiple cystic 
lesions were only followed up till the surgical excision of the largest cyst. Thereafter, the final 
dataset contained 711 cases with 980 total images.  
Patients who are found to have more than one category of cystic pancreatic pathology were 
not excluded as the features of each cyst were studied and applied to the model individually. 
This applies to patients in whom the discovered cysts are not of the histological category of 
interest in this study. Figure 1 summarises the patient selection processes. 
2.2 Missing Data 
Data on the subjective sensation of pruritus, family history of pancreatic cancer and past history 
of malignancy was not available for all cases from the electronic medical record. Furthermore, 
certain radiological data were not available in all imaging reports in the electronic medical 
record. For complete and minimally biased analysis, data was imputed under a mathematical 
framework called multiple imputation by chained equations, a technique now recommended as 
standard practice. By this framework, each variable was imputed by borrowing information 
from the remaining variables called multiple imputation by chained equations. (34) In this 
technique, missing data in each variable is imputed via a regression on the remaining variables 
that were highly correlated with variable containing missing data. (35)  
2.3 Model development 
The model that appropriately addresses the problem laid out previously must have the 
following properties: 
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 It must be able to address a trichotomous outcome (i.e. prediction of either SCA, MCN 
or IPMN) where outcomes are considered mutually exclusive 
 It must be explicable for example by expressing the effect of each variable towards the 
prediction of any particular outcome 
This is essential for its acceptability in routine clinical practice 
 It should ideally account for uncertainly in predictors (independent variables) 
Since all imaging modalities are not proved to have adequate reliability in detecting 
features the model should account for uncertainly in the data 
 It should ideally account for longitudinal data since suspected cystic pancreatic 
neoplasms may be placed on surveillance if immediate surgical intervention is not 
desired 
Explicable statistical methods that account for trichotomous outcomes are multinomial logistic 
regression and a tree-based classification algorithm known as conditional inference tree which 
have been described previously. (36,37) 
Briefly, the multinomial logistic regression model is exactly the same as the logistic regression 
model in that one of the outcome categories is considered baseline. The regression coefficients 
therefore describe the effects of the independent variables on the probability of predicting for 
the alternate outcome as opposed to the baseline outcome on a log scale. The difference is that 
the multinomial logistic model is capable of running two or more regressions against the 
baseline outcome. These regressions inform each other through the constraint that their 
predicted probabilities must sum to one. 
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The multinomial logistic regression may be executed under a Bayesian framework to account 
for uncertainty in the predictors as described by Ntzoufras (38). Non-informative prior 
distributions is assigned to the regression coefficients. The standard deviations of the prior 
distributions of categorical variables may be linked by hyper-priors. (39) This is done because 
the presence of one level of a categorical variable is in fact informative of the absence of the 
rest. Finally, a random effect variable may be introduced to account for multiple surveillance 
images taken before deciding to operate on a patient. 
The Conditional Inference Tree also has its roots in statistical inference methods as opposed to 
traditional tree based methods. this algorithm produced a decision tree by examining variables 
of the model one-by-one to choose the one that gave the greatest classification power. 
Classification power is defined in this methodology on the basis of information theory which 
searches for the minimum number of questions needed to be asked in order to arrive at the 
desired answer. In this case, the algorithm searched for the least number of questions that 
need to be answered about the cyst in order to determine its histological subtype. 
After selecting a variable, the algorithm examined splits (for categorical variables) or cut-off 
points (for continuous variables) in the selected variable once again to select one that afforded 
the greatest classification power. Both variable and split selections were guided by statistical 
criteria based on p-values. This process was repeated to produce steps of a decision tree until 
the statistical criteria could not be satisfied further. Variables that had already been selected at 
a higher level in the decision tree could be reconsidered for a lower level in the decision tree. 
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Unfortunately there does not currently exist and implementation for classification trees under 
the Bayesian framework. Moreover, the conditional inference tree does not yet support 
longitudinal data. It would therefore seem that Bayesian multinomial logistic regression would 
be the most appropriate tool for this problem. However, this methodology requires a few 
important considerations in order for its application to be legitimate. Agresti states that, as a 
rule of thumb, the dataset must contain 10  - 25 cases for each independent variable included 
in the model. The introduction of priors (and hyper-priors) demands that this principle be 
applied conservatively (i.e. 10). In this case, the question arises as to which of the independent 
variables under consideration can be included in this model. 
One way is to train multiple models by forward or backward selection. This is not feasible since 
the Bayesian framework is implemented computationally, and not mathematically, via a set of 
sampling methods known as Markov Chain Monte Carlo methods. The properties of these 
methods, demand that computations with large number of iterations be run in order to 
produce results that are not auto-correlated and reflect the true posterior distribution of the 
coefficients (see Kruschke (39) for details).  With the aforementioned sample size, such a 
computation can take days to complete even on a computational cluster. Therefore, more 
efficient method is needed to select independent variables of interest. 
The properties of the Conditional Inference Tree make it suitable for this task. Variables with 
poor reliability will not be very good at predicting for the outcome. These variable will not make 
it through the variable selection process of the Conditional Inference Tree. Therefore, at the 
expense of the ability to examine the effects of unreliability and longitudinal data on prediction, 
the Conditional Inference Tree was chosen. (This is why pre-operative surveillance images were 
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excluded in the selection process) The intention was to develop the rudiments of a tool 
incorporating the bare essentials for predicting for cystic pancreatic neoplasms histology and 
examining the performance yielded therein.  
2.4 Model Evaluation 
The resulting decision tree was then evaluated for its ability to accurately classify cases into the 
correct histological subtype of cystic pancreatic neoplasm by constructing a receiver operating 
curve surface (ROCS), a methodology put forward by Mossman. This surface is equivalent to the 
receiver operating curve except it is designed to evaluate the performance of three outcomes 
groups. The volume under the ROCS (VUS) was used as a summary measure of assessment of 
classification. This is equivalent to the area under the receiver operating curve (AUC) except, 
once again, it is designed to evaluate three outcome groups. (40) Furthermore, the models’ 
ability to distinguish between SCN vs. non-SCN category of cystic pancreatic neoplasm was 
examined considering that misclassification in this regard had the greatest cost. 
2.5 Sensitivity Analysis 
To understand the effects of uncertainty in the data on the performance of the decision tree, 
five sets of data were imputed using the imputation process described above. Doing so had the 
effect of producing datasets that preserved the properties of the original dataset such as the 
proportion of levels in categorical variables yet introducing a “jitter” in the dataset making each 
imputed dataset slightly different. The decision tree was then trained on the first dataset and 
tested against each of the other four datasets in a manner similar to Carpenter at al. (41) The 
four resulting VUS were compared against each other. 
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Subsequently, the decision tree was evaluated by cross-validating bootstrapped datasets (42): 
three-fourths of the dataset was randomly selected (with replacement) to create a training set 
on which the decision tree was trained following which the remaining one-fourth was used to 
test the trained decision tree. This process was repeated 10,000 times to produce a distribution 
of VUS estimates. This bootstrap method provided a more rigorous method of sensitivity 
analysis whereby the properties of the original dataset were not preserved allowed for 
examination of performance under “extreme” conditions. 
2.6 Software 
The entirety of the study was conducted in the R statistical programming language. (43) Missing 
data imputation was performed using the mice package (35). The conditional inference tree 
was developed using the partykit package (37). The 3-way ROCS and the volume under the 
ROCS was computed by programming Mossman’s mathematical logic into R code. The trained 
decision tree was programmed into a simple interface requiring the elements needed to make a 
decision using the shiny package. (44) 
3.  Results 
3.1 Patient Characteristics 
Table 3 summarises the characteristics of patients according to diagnosed cyst type. The 
dataset consisted of 711 patients, comprising 422 IPMNs (60.9%), 219 SCNs (27.4%) and 71 
MCNs (11.6%). The mean age (SD) of the patients was 64.1 ± 13.6 years. Fifty-nine percent of 
the patients were female.  Eighty-two percent of the population were Whites with the 
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remainder comprising of 9.6 %, 3.2 %, 4.5 % African Americans, Asians and other respectively. 
Sixteen percent of the patients had diabetes. Eighteen percent of the patients had a past 
history of malignancy. Fourteen percent of the patients had a family history of malignancy. The 
mean (SD) largest diameter of cysts was 3.73 ± 2.50 mm on CT. Forty percent of cysts were 
location in the tail region, 39.8 % in the head region and the remainder in the neck region. Cyst 
characteristics have been reported for CT images since these images have the least amount of 
missing data. 




(n = 711) 
IPMN 
(n = 421) 
SCN 
(n = 219) 
MCN 
(n = 71) 
Patient Characteristics, n unless otherwise specified 
Female Sex 422  203 150  69 
Ethnicity 




68 24 29 15 
Asian 23 8 11 4 
Other 32 17 10 6 








289 190 75 24 
Pruritus (n 
= 530) ξ 
26 19 7 0 
Weight 
Loss 
107 96 10 1 
Jaundice 66 61 5 0 
Diabetes (n 
= 705) ξ 
112 74 29 9 
Nausea and 
Vomiting 
(n = 667) ξ 




112 56 53 3 
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Cancer (n = 
446) ξ 
64 44 14 6 












































Location of Cyst in Pancreas 
Head 
Region 
259 33 92 186 22 69 72 10 23 1 1 0 
Neck 
Region 
47 5 7 27 3 5 16 1 2 4 1 0 
Tail 
Region 





211 30 86 108 18 77 83 0 0 20 12 2 
Presence of 
Calcificatio
ns in Cyst 
























71 7 0 67 4 0 4 1 0 0 2 0 
ξ data reported is that which was available from the electronic medical record 
η  data reported from CT only 
3.2 Decision Tree 
Figure 2 shows the decision tree as developed by the conditional inference tree algorithm. The 
tree branches at variables which were statistically significant for providing classification power; 
these variables are as follows: 
1. Calcification of the cyst (CALCI) 
2. Common Bile Duct Dilation (CBD) 
3. Location of the tumour within the pancreas (LOCATION) 
4. Head Region 
5. Neck Region 
6. Tail Region 
7. Age of the patient (AGE) 
8. Largest diameter of the cyst (LARGEST) 
9. Main Pancreatic Duct Dilation (MPD) 
10. Presence of a thick cyst wall (WALL) 
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11. History of Past Malignancy in the patient (pancreatic or other) (PAST.MALIG) 
12. Gender of the patient (GENDER) 
The words in parenthesis correspond to the abbreviations used at the branches of the decision 
tree. The type of imaging modality used to detect the cystic lesion was not significant in the 
tree building algorithm along with: 
1. Ethnicity 
2. History of weight loss 
3. History of abdominal pain 
4. History of jaundice 
5. History of pruritus 
6. History of nausea and/or vomiting 
7. Family history of pancreatic cancer 
8. History of diabetes 
9. Presence of septations in the cyst 
10. Presence of mural nodule(s) in the cyst 
3.3 Evaluation 
Figure 3 shows the receiver operating curve surface for the decision tree as trained against the 
first imputed dataset and tested against the second. The volume under the surface (meaning 
the probability of correctly classifying SCNs, MCNs and IPMNs) was 77.5% (p < 0.001). The 
remaining 23% that was not correctly classified comprised of 36.2% of SCNs that were 
misclassified as IPMNs or MCNs and 15.9% of non-SCN cases that were misclassified as SCNs. 
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Table 2 shows VUSs obtained by testing the decision tree against all imputed data sets. 
Test Set VUS 
Imputed Set 2 77.5 
Imputed Set 3 77.4 
Imputed Set 4 72.4 
Imputed Set 5 76.8 
Table 4: Volumes Under Surface for testing against imputed data sets 
Figure 4 shows the distribution of bootstrapped VUS values. The mean VUS value was 66% with 
a 95% confidence interval of 54.5% - 78.5%. 
3.4 Clinical Application 
Figure 5 shows a screenshot of ‘shiny’ interface to the trained decision tree. It displays the most 
likely outcome as well as displays a bar chart of the probabilities of the other possibilities.  
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4. Discussion 
Adequate diagnosis of cystic pancreatic lesions as yet remains a matter of expert opinion 
especially because of the multidisciplinary approach required and because a significant amount 
of experience is necessary to overcome the subjective elements in the process. The decision 
tree developed in this paper provides a solid foundation for capturing this complex process to 
harness it into a simple interface. Such an interface can imbue efficiency into the diagnosis 
process on a larger scale that is not limited by the time it takes to develop the clinical acumen 
that traditionally has allowed such efficiency. It can do so with an accuracy that is equivalent to 
current expert clinical practice. 
The decision tree has simplified the diagnostic process by narrowing it to the most statistically 
significant variables necessary to achieve maximum diagnostic accuracy. Furthermore, the 
interface to the decision tree provides a simple checklist to coordinate the data collection from 
different modalities involved. 
Many a times, the pancreas is peppered with cysts and the surgeon may only want to resect the 
one(s) that appear most threatening in the interest of preserving some pancreatic function. The 
decision tree has been developed with the intention of focusing on a single cyst thereby 
supporting considerations in resection and surveillance strategies to be made at an individual 
cyst level. 
The decision tree has been developed with a basic clinical question in mind: what is the 
histology of the cystic lesion in question? Answering this question has two major utilities: first, 
the clinician can incorporate biological knowledge regarding the natural history and potential 
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for malignancy of the cystic lesion to assist decision to resect versus surveillance; second, the 
clinician can also use to decision tree to “tag” cystic lesions in patients who have been placed 
on surveillance in order to follow them in the long run to study the nature and appearance of 
malignant features. The latter utility offers the advantage of more detailed understanding of 
the individual natural histories of each of the cystic pancreatic neoplasms, which in turn can aid 
tailoring of resection and surveillance strategies specific to each subtype. 
Moreover, this foundation can be built upon to push the accuracy of diagnosis higher (we use 
the term accuracy for a lack of equivalent terms to sensitivity and specificity in the 3 outcome 
case). Recent studies have highlighted the potential value of molecular markers (45) in 
providing this added accuracy and such data could be incorporated into the decision tree. 
Other, though lower yield, additions entail further exploration of biochemical markers in cyst 
fluid. Ryu et al., in a cohort of 56 cystic fluid aspirates, identified that 86.7% of the mucinous 
cystic tumours (MCAs and IPMNs combined) displayed CEA levels > 400 ng/dL whereas the 
highest CEA level among 8 SCNs was 57 ng/dL. They concluded that a CEA threshold of 467 
ng/dL had a sensitivity of 87% and a specificity of 98% for distinguishing between mucinous and 
cysts of any other kind. CA 19-9, on the other hand, did not reveal any discriminatory power 
between cysts. (46) Van der Waaij et al., in their pooled analysis of 12 studies, propose a lower 
CEA cut-off of < 5 ng/mL that distinguishes between mucinous and serous lesions with 54% 
sensitivity and 94% specificity. They also propose a CA 19-9 cut-off of 37 ng/mL to exclude SCNs 
with sensitivity 19% and specificity 98%. (47) 
Brugge et al. report sensitivities and specificities from a compendium of studies that attempted 
to diagnose cystic lesions with CEA with cut-off > 400 ng/mL for mucinous lesions and < 4 
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ng/mL for serous lesions. 14 serous cystadenomas were diagnosed resulting in 54% sensitivity 
and 77% specificity and 17 MCAs were diagnosed resulting in 13% sensitivity and 75% 
specificity. (12) 
The decision tree also needs to be extended to cover peculiar situations that were not 
specifically addressed in this study. For example, some patients present with isolated dilation of 
main pancreatic duct as the only abnormal finding which may actually be a sign of an IPMN. As 
detailed in the Introduction section, SCNs also have an oligocystic variant that has no septations 
or locules and are typically positioned in the pancreas in a manner that make them hard to 
distinguish from MCNs. Addressing these variations in presentation of cysts may be key to 
reducing the misclassification rate of the decision tree. 
4.1 Limitations 
Should there ever be discovered a single modality that diagnoses the category of cystic 
pancreatic neoplasm with very high accuracy (> 80 % in the least), then such a modality would 
obviate the need for this decision tree and modalities employed therein. 
While the decision tree is robust in the face of minor changes to the data set, it is very sensitive 
to the proportion of the tumours in the population being predicted for. This is reflected by the 
bootstrapped values of VUS shown in the previous section. When the proportion of tumours in 
the training and test sets was similar, the performance of prediction exceeded 75%. Conversely, 
when the proportion of tumours in the training and test sets was not similar, then the 
performance of prediction deteriorates going as low as 38%. Therefore, if the decision tree is 
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used to predict for a patient from a population wherein the proportion of tumours does not 
match that of the training set, then an erroneous prediction is to be expected.  
Another factor to consider is that the decision tree was developed on cases with confirmed 
pathological diagnosis meaning that all cystic lesions in these cases were considered 
“concerning” enough to necessitate surgical excision. This biases our results in that the decision 
is only applicable to patients with “concerning” cystic lesions in the pancreas. 
One factor that is fairly arduous to address is the fact that the decision tree was trained on 
cases referred to a tertiary care referral centre that many not be representative of the true 
proportion of tumours in the general population. Concordantly, this decision tree cannot be 
used in community clinics or in specialties outside of general surgery. One may expand the 
dataset by repeating the process in a cross-institutional dataset, but the fact remains that large 
scale and long-term tracking of cystic pancreatic neoplasms is only currently performed at 
tertiary referral centres. 
The decision tree assumes that when a particular feature regarding the cyst is reported, for 
example the presence of cyst calcification, then that features is either definitively present or 
absent. However, in reality poor inter-rater reliability has been reported in detecting certain 
cyst features via imaging modalities. [reference] A Bayesian model may be more appropriate in 
this scenario as uncertainty may lead to different conclusions in predicting for the histology of 
cystic pancreatic neoplasms. 
The behaviour of the decision tree is such that it, whenever it misclassifies a case, it tends to 
misclassify cases in favour of those tumours that are historically known to be more malignant 
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(i.e. more SCNs were misclassified as IPMNs and MCNs than vice versa). This behaviour may in 
fact be an indication that decision tree is capturing the decision-making trends of the surgical 
consultants over the years. Indeed the Fukuoka consensus guidelines were designed to err on 
the side of caution in a similar sense and post-hoc studies that have attempted to assess the 
performance of the Fukuoka consensus guidelines have confirmed as such. This behaviour is, 
therefore, concerning that the decision tree is nothing more than a mathematical 
representation of clinician judgement. Since clinician judgment has been primary oriented 
towards patient welfare and early removal of a potentially curable malignancy, it deviates from 
the primary goal of this study, which was to develop a tool that non-invasively elucidates the 
underlying histology of the cystic pancreatic lesion. Future revisions to this statistical model will 
need to eliminate the effect of the clinician judgment. 
Following the same concern, an important consideration is to employ all diagnostic modalities 
with equal frequency as opposed to current clinician practice, which is to do a EUS with FNA 
most if diagnosis of the cystic lesion on CT and/or MRI remains ambiguous. 
Notwithstanding these limitations, an alternate approach has been detailed in the Methodology 
section that is capable of addressing them. The multinomial logistic regression model, 
computed under the Bayesian framework, can now be used with the variables selected by the 
decision tree. Under these variables, the regression model can be developed with the 
confidence of equal, if not higher, predictive power while examining the effects of uncertainty 
and longitudinal data from pre-operative surveillance images. Furthermore, latent variables can 
be incorporated to account for surveillance cases that do not yet have confirmed pathological 
diagnosis to increase the generalizability of the  tool to a broader range of patients. 
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5. Conclusion 
In conclusion, this study has produced a clinically applicable tool that can be used alongside the 
current Fukuoka guidelines to enhance decision making ability. It can do so for a broad 
population of surgeons that have yet to be galvanised by the experience it takes to master the 
practice of the Fukuoka guidelines. It provides the base for further work that may enhance 





Figure 1: Patient Selection 
900 inpatients and outpatients 
with cystic lesion visualised in 
pancreas
94 unoperated surveillance cases 
excluded
806 inpatients and outpatients 
with confirmed histpathological 
diagnosis of CPN
94 patients on whom radiological 
data was not unavailable
712 patients with 1804 images
824 surveillance images prior to 
surgery excluded




Figure 2: Decision Tree as developed by the Conditional Inference Tree algorithm 
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Figure 3: Receiver Operating Curve Surface (the surface begins at the red star; a perfect surface would look like a 
cube with the outer most corner touching the blue star 
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